Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus.

A technology of thymidylate synthase and heterozygosity, which can be used in biochemical equipment and methods, microbial determination/inspection, drug combination, etc., and can solve problems such as adverse side effects of chemotherapy regimens

Inactive Publication Date: 2006-05-24
RESPONSE GENETICS
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because of the prevalence of adverse side effects with almost all chemotherapy regimens, it is desirable to be able to predict tumor response to chemotherapeutic agents in order to rule out any unnecessary or unsuccessful treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus.
  • Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus.
  • Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus.

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Patient group

[0044] Eligible patients had (a) post-surgical diagnosis of diffuse or recurrent colorectal cancer; (b) Eastern Cooperative Oncology Group of 0 to 2 with appropriate blood, liver, and kidney function Performance status; (c) no treatment during the previous 4 weeks; and (d) lesions measurable by radiographic examination.

[0045] treat

[0046] Patients were treated with S-1 twice daily for 28 days, followed by a 2-week break. S-1 was taken orally after breakfast and dinner. As in previous Phase II studies (Villafranca, E., et al., J. Clin. Oncol., 19: 1779-1786, 2001; Zinzindohoue, F., et al., J. Clin. Oncol., 19: 3442, 2001), Use the body surface area (BSA) to determine the dose of S-1 given as follows: BSA2 , 40mg; 1.25-1.5m 2 , 50mg; >=1.5m 2 , 60mg. These treatments are repeated until disease progression is determined by the treating physician, or at the discretion of the physician.

[0047] This protocol was reviewed and approved by the Facul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for predicting response to chemotherapy regimens based on loss of heterozygosity at the thymidylate synthase locus in cancer tissue. This method comprises determining the genotype of thymidylate synthase in normal tissue of a patient; determining the genotype of thymidylate synthase in tumor tissue of said patient; comparing the genotype of normal tissue with the genotype of tumor tissue; based on the genotype comparison, determining whether loss of heterozygosity at the thymidylate synthase locus occurs in tumor tissue; and predicting response to chemotherapy regimens based on loss of heterozygosity in tumor samples.

Description

Background of the invention [0001] Thymidylate synthase (TS) catalyzes the reductive methylation of 2'-deoxyuridine 5,10-methylenetetrahydrofolate to form 2'-thymidylate and dihydrofolate. This is a necessary step in DNA synthesis. Since TS is the only de novo source of thymine bases and its reaction is one of the rate-limiting steps in DNA synthesis, inhibition of TS is a fruitful approach in cancer chemotherapy (Danenberg, P.V., Biochim. Biophys. Acta, 473:73-92, 1977). TS is the enzyme that targets 5-fluorouracil (5-FU), which has been one of the mainstay drugs in many cancer treatments for almost 50 years. 5-FU inhibits TS by forming a stable ternary complex between 5,10-methylenetetrahydrofolate, TS, and 5-fluoro-2′-deoxyuridine, the active metabolite of 5-FU, thereby exerting its cytotoxic effect. Since the advent of 5-FU, other fluoropyrimidine-based treatments such as FudR, UFT, S-1 and capecitabine and folate-based TS inhibitors such as ratitrexed, pemetrexed or l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCC12Q1/6886C12Q2600/106C12Q2600/158A61P35/00C12Q2600/136
Inventor K·D·达宁伯格
Owner RESPONSE GENETICS